| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(6 years from now) | |
| US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
May, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| US8940756 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(8 years from now) | |
| US11529336 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11576904 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11534432 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11813251 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(16 years from now) | |
| US11850241 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11576903 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11801237 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11844788 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11612591 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(16 years from now) | |
| US11793795 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11850240 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(16 years from now) | |
| US11779572 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Oct, 2042
(18 years from now) | |
Qinlock is owned by Deciphera Pharms.
Qinlock contains Ripretinib.
Qinlock has a total of 23 drug patents out of which 0 drug patents have expired.
Qinlock was authorised for market use on 15 May, 2020.
Qinlock is available in tablet;oral dosage forms.
Qinlock can be used as treatment of gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 arthralgia while being administered ripretinib daily, treatment of gastrointestinal stromal tumors in patients suffering from hypertension, treatment of gastrointestinal stromal tumors, treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor, method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily, treatment of advanced gastrointestinal stromal tumor in patients previously administered at least three tyrosine kinase inhibitors, where one of the kinase inhibitors is imatinib, treatment of gastrointestinal stromal tumors in patients suffering from a grade 3 adverse reaction while being administered ripretinib daily, treatment of gastrointestinal stromal tumor, treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib, treatment of gastrointestinal stromal tumor with a wild type kit mutation in patients previously administered three or more kinase inhibitors, where one of the kinase inhibitors is imatinib, treatment of gastrointestinal stromal tumors in patients having pre-existing severe hepatic impairment and suffering from an adverse event while being administered ripretinib daily, treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome.
Drug patent challenges can be filed against Qinlock from 15 May, 2024.
The generics of Qinlock are possible to be released after 06 October, 2042.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors; Treatment of gastrointestinal stromal tumors in patients suffering from a grade 3 adverse reaction while bein...
Dosage: TABLET;ORAL
QINLOCK family patents
